Ju Hyun Lee

Ju Hyun Lee

Auto-generated profile, based on publicly available information

Ju Hyun Lee

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
SPSang Park
Sang Park
JLJu Hyun Lee
Ju Hyun Lee
SKSe Woong Kang
Se Woong Kang
JHJoon Young Hyon
Joon Young Hyon
KPKyu Hyung Park
Kyu Hyung Park
Park SJ, et al. J Korean Med Sci. 2016 Jun;31(6):963-971. https://doi.org/10.3346/jkms.2016.31.6.963

29 April 2019 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
SYSeung Bae Yoon
Seung Bae Yoon
MCMoon-hyung Choi
Moon-hyung Choi
MSMeiying Song
Meiying Song
JLJu Hyun Lee
Ju Hyun Lee
ILIn Seok Lee
In Seok Lee
MCMyung‐Gyu Choi
Myung‐Gyu Choi
Background: Although surgical resection is the only potentially curative treatment for biliary tract cancer, the prognosis remains poor after a major operation such as pancreatoduodenectomy or hepatectomy. We aimed to investigate the impact of preoperative body compositions on long‐term survival of patients undergoing resection of biliary tract cancer.Methods: We analysed data of patients diagnosed with biliary tract cancer who underwent surgery from 2009 to 2015. Skeletal muscle area, skeletal muscle radiation attenuation, and visceral and subcutaneous adipose tissue areas were measured from the computed tomography images at L3 vertebral levels obtained before resection of cancer. Patients were divided into two groups based on the sex‐specific median values for each parameter, and long‐term survival was compared between the groups.Results: A total of 371 patients (women, 39.6%; mean age, 66.2 ± 9.6 years) were finally included in the analysis. Patients with low skeletal muscle index (SMI) had significantly shorter median survival than those with high SMI (29 vs. 39 months; P = 0.026). Patients with low skeletal muscle attenuation (SMA) also showed reduced survival compared with those with high SMA (median survival 25 vs. 60 months; P = 0.002). Combining these two factors, survival was highest in the high SMI/high SMA group (reference) and lowest in the low SMI/low SMA group (hazard ratio, 2.18; 95% confidence interval, 1.44–3.30). Visceral and subcutaneous adipose tissue areas were not associated with long‐term survival.Conclusions: Low SMI and low SMA on computed tomography scan have a negative impact on survival after resection of biliary tract cancer. They can be used in preoperative risk assessment to assist in treatment decision making.

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JRJiwon Ryu
Jiwon Ryu
RCRan-Hui Cha
Ran-Hui Cha
DKDong Ki Kim
Dong Ki Kim
JLJu Hyun Lee
Ju Hyun Lee
SYSun Ae Yoon
Sun Ae Yoon
AIAPrODiTe investigators
APrODiTe investigators
Ryu J, et al. J Korean Med Sci. 2014 Jul;29(7):957-964. https://doi.org/10.3346/jkms.2014.29.7.957

1 January 2022 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HHHun-Gyu Hwang
Hun-Gyu Hwang
JLJu Hyun Lee
Ju Hyun Lee
SKSang-A Kim
Sang-A Kim
YKYang-Ki Kim
Yang-Ki Kim
HYHo-Young Yhim
Ho-Young Yhim
SBSoo-Mee Bang
Soo-Mee Bang
Hwang HG, et al. J Korean Med Sci. 2022 Apr;37(17):e130. https://doi.org/10.3346/jkms.2022.37.e130

17 January 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
EJEun Hee Jung
Eun Hee Jung
HJHee Ryeong Jang
Hee Ryeong Jang
SKSe Hyun Kim
Se Hyun Kim
KSKoung Jin Suh
Koung Jin Suh
YKYu Jung Kim
Yu Jung Kim
JLJong Seok Lee
Jong Seok Lee
Background: Immune checkpoint inhibitors (ICIs) are an established treatment for non‐small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). Previous studies have suggested NY‐ESO‐1 and LAG‐3 to be surrogate markers of ICI responses in NSCLC; therefore, we explored the predictive value of their expression in NSCLC.Methods: We retrospectively reviewed the records of 38 patients with advanced NSCLC treated with anti‐PD‐1 monoclonal antibodies from 2013 to 2016 at Seoul National University Hospital and Seoul National University Bundang Hospital after failed platinum‐based chemotherapy. Tumor tissues from each patient were subjected to immunohistochemical analysis to determine NY‐ESO‐1, LAG‐3, and PD‐L1 expression, whose ability to predict progression‐free survival (PFS) and overall survival (OS) was then analyzed alongside their positive (PPV) and negative (NPV) predictive values.Results: NY‐ESO‐1 or LAG‐3 expression was detected in all tumor samples from patients with high PD‐L1 expression and was significantly associated with favorable outcomes, unlike PD‐L1 expression. Patients with both NY‐ESO‐1‐ and LAG‐3‐expressing tumors had a high DCB rate and those with triple‐positive PD‐L1, LAG‐3, and NY‐ESO expression had a superior median OS and PFS than those with triple‐negative expression. Furthermore, LAG‐3 and NY‐ESO‐1 co‐expression was an independent predictor of both PFS and OS, while LAG‐3 displayed a good NPV.Conclusions: Patients with NSCLC who co‐express NY‐ESO‐1 or LAG‐3 with PD‐L1 exhibit greater DCBs and improved long‐term survival following anti‐PD‐1 therapy. Moreover, NY‐ESO‐1 and LAG‐3 could be novel predictive biomarkers of survival and should be considered in the future use of ICIs.

1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JLJi Yun Lee
Ji Yun Lee
JLJu-Hyun Lee
Ju-Hyun Lee
JSJeongmin Seo
Jeongmin Seo
MKMinsu Kang
Minsu Kang
EJEun Hee Jung
Eun Hee Jung
SBSoo-Mee Bang
Soo-Mee Bang
Lee JY, et al. J Korean Med Sci. 2024 May;39:e175. https://doi.org/10.3346/jkms.2024.39.e175